Trial record 1 of 195837 for:    ALL
Previous Study | Return to List | Next Study

The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2015 by BioDelivery Sciences International
Sponsor:
Information provided by (Responsible Party):
BioDelivery Sciences International
ClinicalTrials.gov Identifier:
NCT02516436
First received: August 3, 2015
Last updated: August 4, 2015
Last verified: August 2015

August 3, 2015
August 4, 2015
August 2015
December 2015   (final data collection date for primary outcome measure)
Change from Baseline in COWS total score for BEMA Buprenorphine NX vs BEMA Buprenorphine NX Control [ Time Frame: At 12 hours post inital dose ] [ Designated as safety issue: Yes ]
To determine if induction of opioid dependent subjects with BEMA Buprenorphine NX results in more opioid withdrawal symptoms than induction with BEMA Buprenorphine NX Control
Same as current
Complete list of historical versions of study NCT02516436 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects
A Randomized, Double-blind, Active Control Evaluation of the Safety of BioErodible MucoAdhesive (BEMA®) Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

A randomized, double blind, active controlled study in approximately 40 opioid dependent subjects. Study duration is up to five days and includes a maximum of 3 days confinement in the clinic. Opioid dependent subjects who provide informed consent meet all entry criteria are eligible for enrollment into the study.

A randomized, double blind, active controlled study in approximately 40 opioid dependent subjects. The study includes a Screening period of up to 3 days and a 2-day, double blind induction phase (subjects confined to the clinic). Screening and the first day of treatment (Day 1) may occur on the same day or Screening may occur up to 3 days prior to Day 1.

Opioid dependent subjects who provide informed consent at the Screening visit; have a Clinical Opiate Withdrawal Scale (COWS) total score ≥12; and meet other entry criteria are eligible for enrollment into the study. Subjects will be confined to the clinic beginning on Day 1 (optional confinement on Day -1) and will remain there for up to 48 hours after administration of the first study drug dose.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Opioid Dependence
  • Drug: BEMA Buprenorphine NX
    Buprenorphine with naloxone
    Other Name: Bunavail
  • Drug: Buprenorphine
    Buprenorphine
  • Experimental: BEMA Buprenorphine NX
    Buprenorphine with naloxone in a buccal film
    Intervention: Drug: BEMA Buprenorphine NX
  • Active Comparator: Buprenorphine
    Buprenorphine in a buccal film
    Intervention: Drug: Buprenorphine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
40
December 2015
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Signed informed consent obtained prior to any study procedure being performed
  2. Pre-specified plan for continued treatment following study participation
  3. Male or non-pregnant and non-nursing female. A female of childbearing potential is eligible to participate in this study if she is not pregnant and is using an acceptable method of birth control.
  4. Subject is aged 18 to 55 years, inclusive
  5. Current diagnosis of opioid substance use disorder per the Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5)
  6. Clinical opioid withdrawal scale (COWS) total score ≥12 prior to dosing on Day 1
  7. Subject is otherwise in good general health in the judgment of the Investigator as determined from the physical and oral examination findings.
  8. Subject is committed to getting help for their opioid dependence, in the judgment of the Investigator.
  9. Subject has at least 1 verified contact.

Exclusion Criteria:

  1. Inability to meet study participation requirements, including a stay of up to 2 nights in the clinic
  2. Positive buprenorphine or methadone result on urine drug screen at Screening or Baseline
  3. Concurrent Diagnostic and Statistical Manual of Mental Disorders - 5th edition diagnosis of substance use disorder (excluding opioids and tobacco)
  4. Prolonged QT interval by medical history, family history, or current electrocardiogram (ECG) finding
  5. History of clinically significant hepatic impairment as determined by the Investigator.
  6. Use of any medication, nutraceutical or herbal product with CYP3A4 inhibition or induction properties within the past 30 days. This exclusion also extends to grapefruit juice and grapefruit juice-containing products as well as St. John's wort and St. John's wort-containing products (prescription or nonprescription drugs, vitamins, minerals, or dietary/herbal supplements).
  7. Use of an investigational drug or device within the last 30 days
  8. History of hypersensitivity, allergy, or intolerance to buprenorphine or naloxone
  9. Increased suicidal risk, as determined by meeting any of the following:

    • History of suicidal ideation ≤ 3 months prior to Baseline with a score of 4 (intent to act) or 5 (specific plan and intent) on the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
    • History of suicidal behavior ≤1 year prior to Baseline (actual attempt, interrupted attempt, aborted attempt and/or preparatory acts/behavior) on the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
  10. Lack of motivation or a pattern of prior poor response to treatment, as judged by the investigator
  11. A history or current evidence of any clinically significant disorder or any other condition which in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results
Both
18 Years to 55 Years
No
Contact: Tim M Warneke, MS 919-582-0294 twarneke@bdsi.com
Contact: Sally Wilging, RN 919-582-0288 swilging@bdsi.com
United States
 
NCT02516436
BNX-302
No
BioDelivery Sciences International
BioDelivery Sciences International
Not Provided
Principal Investigator: James G Sullivan, MD Parkway Medical Center
BioDelivery Sciences International
August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP